摘要
目的 :探讨耐药基因蛋白P gp、GSTπ和TopoⅡ在胃癌中的表达及其临床意义。方法 :应用S P免疫组化法对 85例胃癌进行检测。结果 :胃癌组织P gp、GSTπ表达率分别为 37 6 5 %及 6 3 5 3% ,表达强度与临床分期有关 ,其中高分期者P gp表达较低分期者为高。TopoⅡ表达率为 5 5 2 9% ,阳性率与组织学分类相关 ,分化较低者 (5 9 5 7% )较分化较高者 (38 30 % )阳性率高。结论 :P gp、GSTπ、TopoⅡ的耐药机制各不相同 ,根据P gp、GSTπ和TopoⅡ表达情况进行药物选择对胃癌化疗具有重要的指导意义。
Purpose To investigate the expression and their clinical significance of Pgp,GSTπ and TopoⅡ in gastric carcinoma. Methods Eight five cases of tissue samples of gastric carcinoma were examined by S P immunohistochemical staining. Results The positive expression rates of P gp and GSTπ in gastric carcinoma were 37 65% and 63 53% respectively, which were correlated with TNM stage. The expression of P gp was stronger in late stage than that in early stage of gastric carcinoma. The positive rate of TopoⅡ in gastric carcinoma was 55 29% and was dependent on degree of differentiation, which was higher in poor differentiated tumor (59 57%) than that in well differentiated one (38 30%). Conclusions The mechanisms of drug resistance of P gp, GSTπ and TopoⅡ in gastric carcinoma are different. To achieve better therapeutic efficacy,appropriate chemotherapeutic agents should be given to patients with low expression of P gp and GSTπ but high expression of TopoⅡ.
出处
《临床与实验病理学杂志》
CAS
CSCD
2002年第4期389-392,共4页
Chinese Journal of Clinical and Experimental Pathology
